Document is current

Article History

Received: 6 May 2024

Accepted: 14 August 2024

First Online: 29 August 2024

Declarations

:

: The study protocols were approved by the Research Ethics Committee of the Northern Savo Hospital district (statement 80/2014), and Tampere University Hospital (R15149). The studies were conducted in compliance with the Declaration of Helsinki (as revised in 2013). A written informed consent was obtained.

: Not applicable.

: Competing interests: E.S. congress travel costs from Sanofi Finland, Orion Pharma and Astra Zeneca, virtual congress costs from Roche, owns personal stocks from Orion Pharma Ltd, Board member of Finnish allergology- and immunology association outside the submitted work. M.M. personal consulting fee and lecture fee from Boehringer Ingelheim and Astra Zeneca, congress travel and admission cost from Boehringer Ingelheim outside the submitted work. H.H. personal lecture fee from Boehringer Ingelheim outside the submitted work. H.N. personal lecture fees from Boehringer Ingelheim, Duodecim and Nordic Health Group, congress travel costs from Boehringer Ingelheim, and Duodecim outside the submitted work. S.S. owns personal stocks from Merck & Co, CRISPR Therapeutics, 3 M, Organon & Co, Pfizer outside the submitted work. H-P.K. personal lecture fee from Finnish thoracic radiologist society outside the submitted work. R.K. personal consulting fee from Boehringer Ingelheim and MSD and lecture fee from Boehringer Ingelheim, virtual congress travel costs from Novartis, Board member of the Finnish Lung Health Association and the Finnish Medical Foundation outside the submitted work. MP: personal lecture fee from Boehringer Ingelheim and Hengitysyhdistys, advisory board member of Boehringer Ingelheim outside the submitted work. HOK: personal lecture fee from Boehringer Ingelheim, MSD, Chiesi Pharma, owns personal stocks from Orion Pharma Ltd outside the submitted work. E.L-B. declares no competing interests.